JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Search

Schrodinger Inc

Geschlossen

BrancheGesundheitswesen

12.31 3.45

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

11.9

Max

12.48

Schlüsselkennzahlen

By Trading Economics

Einkommen

169M

136M

Verkäufe

33M

87M

EPS

-0.18

Gewinnspanne

155.644

Angestellte

850

EBITDA

67M

36M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+55.19% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

40M

867M

Vorheriger Eröffnungskurs

8.86

Vorheriger Schlusskurs

12.31

Nachrichtenstimmung

By Acuity

50%

50%

186 / 347 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Schrodinger Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

30. Apr. 2026, 23:08 UTC

Ergebnisse

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. Apr. 2026, 23:07 UTC

Ergebnisse

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. Apr. 2026, 22:20 UTC

Ergebnisse

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30. Apr. 2026, 23:48 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

30. Apr. 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

30. Apr. 2026, 23:47 UTC

Market Talk

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30. Apr. 2026, 23:27 UTC

Market Talk

Liontown Lithium Recovery Expected to Improve -- Market Talk

30. Apr. 2026, 23:22 UTC

Ergebnisse

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30. Apr. 2026, 23:20 UTC

Market Talk

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30. Apr. 2026, 22:52 UTC

Ergebnisse

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30. Apr. 2026, 22:33 UTC

Ergebnisse

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30. Apr. 2026, 22:32 UTC

Ergebnisse

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30. Apr. 2026, 22:32 UTC

Ergebnisse

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30. Apr. 2026, 22:24 UTC

Akquisitionen, Fusionen, Übernahmen

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30. Apr. 2026, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30. Apr. 2026, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30. Apr. 2026, 22:23 UTC

Akquisitionen, Fusionen, Übernahmen

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30. Apr. 2026, 22:11 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

30. Apr. 2026, 22:11 UTC

Market Talk

Global Equities Roundup: Market Talk

30. Apr. 2026, 22:11 UTC

Market Talk

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30. Apr. 2026, 22:05 UTC

Ergebnisse

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30. Apr. 2026, 21:57 UTC

Ergebnisse

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30. Apr. 2026, 21:56 UTC

Ergebnisse

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30. Apr. 2026, 21:56 UTC

Ergebnisse

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30. Apr. 2026, 21:55 UTC

Ergebnisse

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30. Apr. 2026, 21:54 UTC

Ergebnisse

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30. Apr. 2026, 21:54 UTC

Ergebnisse

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30. Apr. 2026, 21:53 UTC

Ergebnisse

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30. Apr. 2026, 21:49 UTC

Ergebnisse

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30. Apr. 2026, 21:49 UTC

Ergebnisse

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Peer-Vergleich

Kursveränderung

Schrodinger Inc Prognose

Kursziel

By TipRanks

55.19% Vorteil

12-Monats-Prognose

Durchschnitt 18.25 USD  55.19%

Hoch 20 USD

Tief 13 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Schrodinger Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

5 ratings

4

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

23.27 / 26.13Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Very Strong Bullish Evidence

Langfristig

Very Strong Bullish Evidence

Stimmung

By Acuity

186 / 347 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
help-icon Live chat